Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect ...

GLP-1RA vs insulin use was associated with improved cardiovascular and kidney outcomes among patients with type 2 diabetes on dialysis.

Italy: A recent analysis of the FDA Adverse Event Reporting System (FAERS) database has provided new insights into the safety ...

Amsterdam, Netherlands) A pioneering study, presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in ...

While this falls outside the scope of the present paper, we encourage other researchers with access to clinical data on GLP-1RA responses in individuals taking cholesterol lowering agents to share ...

Semaglutide and tirzepatide are both glucagon-like peptide-1 receptor agonists or GLP-1 agonists. Although originally prescribed to treat type 2 diabetes (Ozempic and Mounjaro), semaglutide and ...

With these results, they also estimate that if everyone in this broader population of potentially eligible patients took GLP-1s, it could result in 34,000 fewer heart attacks and strokes each year ...

Incretin therapies based on GLP-1 receptor agonism aid in the loss of weight in obesity, but a relevant part of this loss (25%-40%) is attributed to loss of lean muscle mass, which raises the risk of ...